154 related articles for article (PubMed ID: 37781235)
21. High-Plex Spatially Resolved RNA and Protein Detection Using Digital Spatial Profiling: A Technology Designed for Immuno-oncology Biomarker Discovery and Translational Research.
Beechem JM
Methods Mol Biol; 2020; 2055():563-583. PubMed ID: 31502169
[TBL] [Abstract][Full Text] [Related]
22. Association of Machine Learning-Based Assessment of Tumor-Infiltrating Lymphocytes on Standard Histologic Images With Outcomes of Immunotherapy in Patients With NSCLC.
Rakaee M; Adib E; Ricciuti B; Sholl LM; Shi W; Alessi JV; Cortellini A; Fulgenzi CAM; Viola P; Pinato DJ; Hashemi S; Bahce I; Houda I; Ulas EB; Radonic T; Väyrynen JP; Richardsen E; Jamaly S; Andersen S; Donnem T; Awad MM; Kwiatkowski DJ
JAMA Oncol; 2023 Jan; 9(1):51-60. PubMed ID: 36394839
[TBL] [Abstract][Full Text] [Related]
23. A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Melanoma.
Girault I; Adam J; Shen S; Roy S; Brard C; Faouzi S; Routier E; Lupu J; Warren S; Sorg K; Ong S; Morel P; Scoazec JY; Vagner S; Robert C
Clin Cancer Res; 2022 Feb; 28(3):518-525. PubMed ID: 34785583
[TBL] [Abstract][Full Text] [Related]
24. Analysis of Immunological Characteristics and Genomic Alterations in HPV-Positive Oropharyngeal Squamous Cell Carcinoma Based on PD-L1 Expression.
Xu SM; Shi CJ; Xia RH; Wang LZ; Tian Z; Ye WM; Liu L; Liu SL; Zhang CY; Hu YH; Zhou R; Han Y; Wang Y; Zhang ZY; Li J
Front Immunol; 2021; 12():798424. PubMed ID: 35145511
[TBL] [Abstract][Full Text] [Related]
25. Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer.
Wang SJ; Khullar K; Kim S; Yegya-Raman N; Malhotra J; Groisberg R; Crayton SH; Silk AW; Nosher JL; Gentile MA; Mehnert JM; Jabbour SK
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020239
[TBL] [Abstract][Full Text] [Related]
26. Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors.
Zhou JG; Donaubauer AJ; Frey B; Becker I; Rutzner S; Eckstein M; Sun R; Ma H; Schubert P; Schweizer C; Fietkau R; Deutsch E; Gaipl U; Hecht M
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33593828
[TBL] [Abstract][Full Text] [Related]
27. Advanced Molecular Characterization Using Digital Spatial Profiling Technology on Immunooncology Targets in Methylated Compared with Unmethylated IDH-Wildtype Glioblastoma.
Barber H; Tofias A; Lander B; Daniels A; Gong J; Ren Y; Ren X; Liang Y; White P; Kurian KM
J Oncol; 2021; 2021():8819702. PubMed ID: 33995529
[TBL] [Abstract][Full Text] [Related]
28. A high OXPHOS CD8 T cell subset is predictive of immunotherapy resistance in melanoma patients.
Li C; Phoon YP; Karlinsey K; Tian YF; Thapaliya S; Thongkum A; Qu L; Matz AJ; Cameron M; Cameron C; Menoret A; Funchain P; Song JM; Diaz-Montero CM; Tamilselvan B; Golden JB; Cartwright M; Rodriguez A; Bonin C; Vella A; Zhou B; Gastman BR
J Exp Med; 2022 Jan; 219(1):. PubMed ID: 34807232
[TBL] [Abstract][Full Text] [Related]
29. Combined VLA-4-Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma.
Choi J; Beaino W; Fecek RJ; Fabian KPL; Laymon CM; Kurland BF; Storkus WJ; Anderson CJ
J Nucl Med; 2018 Dec; 59(12):1843-1849. PubMed ID: 29959213
[TBL] [Abstract][Full Text] [Related]
30. Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review.
Ouwerkerk W; van den Berg M; van der Niet S; Limpens J; Luiten RM
Melanoma Res; 2019 Oct; 29(5):453-464. PubMed ID: 30855527
[TBL] [Abstract][Full Text] [Related]
31. HEV-associated dendritic cells are observed in metastatic tumor-draining lymph nodes of cutaneous melanoma patients with longer distant metastasis-free survival after adjuvant immunotherapy.
Bravo AI; Aris M; Panouillot M; Porto M; Dieu-Nosjean MC; Teillaud JL; Barrio MM; Mordoh J
Front Immunol; 2023; 14():1231734. PubMed ID: 37691949
[TBL] [Abstract][Full Text] [Related]
32. Loss of BAP1 expression is associated with an immunosuppressive microenvironment in uveal melanoma, with implications for immunotherapy development.
Figueiredo CR; Kalirai H; Sacco JJ; Azevedo RA; Duckworth A; Slupsky JR; Coulson JM; Coupland SE
J Pathol; 2020 Apr; 250(4):420-439. PubMed ID: 31960425
[TBL] [Abstract][Full Text] [Related]
33. Homologous recombination repair gene mutations as a predictive biomarker for immunotherapy in patients with advanced melanoma.
You Z; Lv M; He X; Pan Y; Ge J; Hu X; Zheng Y; Huang M; Zhou C; You C
Front Immunol; 2022; 13():871756. PubMed ID: 35990677
[TBL] [Abstract][Full Text] [Related]
34. Exploring Spatial Heterogeneity of Immune Cells in Nasopharyngeal Cancer.
Sobti A; Sakellariou C; Nilsson JS; Askmyr D; Greiff L; Lindstedt M
Cancers (Basel); 2023 Apr; 15(7):. PubMed ID: 37046826
[TBL] [Abstract][Full Text] [Related]
35. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
36. Multi-omic and spatial dissection of immunotherapy response groups in non-small cell lung cancer.
Monkman J; Kim H; Mayer A; Mehdi A; Matigian N; Cumberbatch M; Bhagat M; Ladwa R; Mueller SN; Adams MN; O'Byrne K; Kulasinghe A
Immunology; 2023 Aug; 169(4):487-502. PubMed ID: 37022147
[TBL] [Abstract][Full Text] [Related]
37. Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti- PD1/PD-L1 immunotherapy in non-small cell lung cancer.
Ghiringhelli F; Bibeau F; Greillier L; Fumet JD; Ilie A; Monville F; Laugé C; Catteau A; Boquet I; Majdi A; Morgand E; Oulkhouir Y; Brandone N; Adam J; Sbarrato T; Kassambara A; Fieschi J; Garcia S; Lepage AL; Tomasini P; Galon J
EBioMedicine; 2023 Jun; 92():104633. PubMed ID: 37244159
[TBL] [Abstract][Full Text] [Related]
38. Tumor Immune Microenvironment Characterization Identifies Prognosis and Immunotherapy-Related Gene Signatures in Melanoma.
Liu D; Yang X; Wu X
Front Immunol; 2021; 12():663495. PubMed ID: 34025664
[TBL] [Abstract][Full Text] [Related]
39. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
40. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
